First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?

被引：1
|
作者：
Bouzianas, Dimitrios [1 ,3 ]
Bouziana, Stella [2 ]
机构：
[1] BReMeL Biopharmaceut & Regenerat Med Labs, Thessaloniki, Greece
[2] Kings Coll Hosp London, Dept Hematol, London, England
[3] BReMeL Biopharmaceut & Regenerat Med Labs, 4th Thermaikou str, Thessaloniki 55534, Greece
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2024年 / 20卷 / 01期
关键词：
CAR T-cells; tisagenlecleucel; B-acute lymphoblastic leukemia; immunotherapy; long-term remission; cure;
D O I：
10.1080/21645515.2024.2321678
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia
    Wang, Xiangmin
    Zhang, Bingpei
    Zhang, Qing
    Zhou, Hongyuan
    Sun, Qian
    Zhou, Yi
    Li, Tianci
    Zhou, Dian
    Shen, Ziyuan
    Zhang, Jiaoli
    Li, Ping
    Liang, Aibin
    Zhou, Keshu
    Han, Lu
    Hu, Yongxian
    Yang, Yun
    Cao, Jiang
    Li, Zhenyu
    Xu, Kailin
    Sang, Wei
    CANCER, 2024, 130 (15) : 2660 - 2669
  • [2] Anti-CD19 chimeric antigen receptor T-cell therapy for B-cell acute lymphoid leukemia
    Rapoport, Aaron P.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1019 - 1020
  • [3] Anti-CD19 chimeric antigen receptor T-cell therapy for B-cell acute lymphoid leukemia
    Rapoport, Aaron P.
    HAEMATOLOGICA, 2024, 109 (04) : 1019 - 1020
  • [4] Modeling Retreatment of Acute Lymphoblastic Leukemia with Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
    Yang, Yinmeng
    Kohler, Mark Eric
    Fry, Terry J.
    BLOOD, 2016, 128 (22)
  • [5] Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
    Cappell, Kathryn M.
    Sherry, Richard M.
    Yang, James C.
    Goff, Stephanie L.
    Vanasse, Danielle A.
    McIntyre, Lori
    Rosenberg, Steven A.
    Kochenderfer, James N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3805 - +
  • [6] Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
    Ursu, Renata
    Maillet, Didier
    Belin, Catherine
    Moroni, Christine
    Cuzzubbo, Stefania
    Vernier, Victoria
    Sirven-Villaros, Lila
    Carreau, Christophe
    Di Blasi, Roberta
    Thieblemont, Catherine
    Carpentier, Antoine F.
    NEUROLOGY, 2022, 99 (12) : 511 - 515
  • [7] T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy
    Martin, Lisa J.
    Whitmore, James B.
    Shen, Rhine R.
    Neumann, Frank
    BLOOD ADVANCES, 2024, 8 (15) : 4144 - 4148
  • [8] Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
    Karschnia, Philipp
    Rejeski, Kaj
    Subklewe, Marion
    von Baumgarten, Louisa
    NEUROLOGY, 2023, 100 (14) : 687 - 688
  • [9] Editors' Note: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
    Lewis, Ariane
    Galetta, Steven
    NEUROLOGY, 2023, 100 (14)
  • [10] Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia
    Liu, Y.
    Chen, X.
    Han, W.
    Zhang, Y.
    DRUGS OF TODAY, 2017, 53 (11) : 597 - 608
12345